FloridaTaper

Category: Withdrawal

  • Stellate Ganglion Block for Benzodiazepine Withdrawal: Could Resetting Sympathetic Tone Break a Crisis?

    Stellate Ganglion Block for Benzodiazepine Withdrawal: Could Resetting Sympathetic Tone Break a Crisis?

    The stellate ganglion block, often abbreviated as SGB, is a procedure that has moved from a niche pain medicine intervention into wider clinical use over the past two decades. It is currently being explored as a possible tool for benzodiazepine withdrawal and BIND, particularly in patients whose dominant features point to a nervous system stuck in sympathetic overdrive. The evidence base in benzodiazepine patients specifically is limited, but the underlying mechanism is plausible enough that the procedure is worth understanding for any patient or clinician thinking about advanced options.

    This is not a recommendation. It is a description of what SGB is, why it has come up in benzodiazepine circles, and what the procedure can and cannot reasonably be expected to do.

    The Sympathetic Overdrive Picture

    One of the most consistent features of benzodiazepine withdrawal and BIND is autonomic dysregulation, and within that broader picture, the dominant pattern is often sympathetic overdrive. The patient’s resting heart rate is elevated. Blood pressure can be labile. Body temperature does not stabilize. Sleep is disrupted by a system that cannot drop into a parasympathetic state. The patient describes a constant sense of being on alert, a low-grade fight-or-flight tone that does not match anything in the external environment.

    This pattern reflects the loss of GABA-mediated inhibition that benzodiazepines were previously providing. With that inhibitory tone gone, sympathetic outflow runs at a higher set point than the body was running before the medication, and the parasympathetic system has lost its counterweight. The result is a nervous system that cannot find its way back to baseline through the usual self-regulating processes.

    Many of the most distressing symptoms of advanced withdrawal can be traced back to this state. Akathisia, insomnia, autonomic instability, sensory hypersensitivity, and the sense of being unable to rest all share this sympathetic-overdrive thread. If a procedure could interrupt that pattern, even temporarily, it could in principle give the nervous system a window in which to settle.

    What the Stellate Ganglion Block Does

    The stellate ganglion is a cluster of sympathetic nerve cell bodies located in the lower neck, near the level of the sixth and seventh cervical vertebrae. It serves as a major relay point for sympathetic signaling to the head, neck, upper chest, and arms. An SGB is performed by injecting a local anesthetic around the ganglion, typically under ultrasound guidance, which temporarily blocks the sympathetic signals passing through that area.

    The block itself takes only a few minutes and is performed in an outpatient setting. The local anesthetic effect lasts hours, but the proposed therapeutic effect can outlast the anesthetic. The hypothesis is that interrupting sympathetic outflow even briefly can reset the nervous system’s set point, allowing it to return to operation at a less hyperactive level.

    How SGB Came to Be Considered

    Stellate ganglion blocks have been used for decades in pain medicine, particularly for complex regional pain syndrome and certain neuropathic pain conditions involving the upper extremities. In the past fifteen years, the procedure has been studied for post-traumatic stress disorder, with reports that it can produce reductions in PTSD symptoms in a subset of patients. The mechanism is thought to involve resetting the autonomic nervous system in a way that quiets the overactive sympathetic signaling that drives many PTSD features.

    Because the symptom pattern in benzodiazepine withdrawal and PTSD share certain features, particularly the persistent sympathetic activation, attention has turned to whether SGB might offer benefit in benzodiazepine-injured patients. Anecdotal reports from patients who have tried it range from no effect to substantial improvement, with most patients in the middle reporting some reduction in symptoms that may not be permanent.

    What Patients Report After SGB

    The pattern of patient reports is uneven, which is consistent with what is seen in PTSD work as well. Some patients describe noticeable calming within hours of the block, with reduced akathisia, easier sleep, and a sense that their nervous system has “let go” of a baseline tension they had not realized was there. Others report no meaningful change. A subset describes mild benefit that fades over days to weeks, leaving them considering a repeat block.

    The patients most likely to report benefit appear to be those whose dominant symptoms map cleanly onto sympathetic overdrive: insomnia driven by inability to relax, akathisia, autonomic instability, and chronic muscle tension. Patients whose primary symptoms are different, such as cognitive fog, mood changes, or gastrointestinal disruption, tend to report less benefit.

    Repeat blocks are sometimes used. The number of blocks needed, and the optimal interval between them, is not well defined for benzodiazepine patients. PTSD protocols often involve a series of two to four blocks over a period of weeks.

    Where the Evidence Stands

    The honest summary is that the evidence for SGB in benzodiazepine withdrawal specifically is limited to clinical reports and patient experience. The mechanism is biologically reasonable. The procedure has a long track record in other contexts. But controlled data in benzodiazepine-injured patients are not yet available in any meaningful volume.

    This places SGB in the category of interventions that may be worth considering for selected patients, particularly when more conservative options have not produced enough relief, but should not be approached as a proven treatment. A patient considering SGB should go in with realistic expectations: it may help, it may not, and the response is difficult to predict in advance.

    What to Consider Before SGB

    Several factors are worth thinking through.

    The procedure should be performed by a clinician experienced in ultrasound-guided SGB. The anatomy of the lower neck contains structures that need to be avoided, and operator experience matters.

    The patient’s overall taper situation should be relatively stable. SGB during an acute, rapidly destabilizing phase of a taper is unlikely to produce the same results as SGB in a patient whose taper has been paused and whose symptom pattern has settled into a recognizable picture.

    Medication interactions and pre-procedure planning are part of what the procedural team will manage. The benzodiazepine patient who is already on minimal medications and who is not in active withdrawal crisis is a more straightforward candidate than the patient with complex polypharmacy or active instability.

    The financial picture should be addressed in advance. SGB performed for benzodiazepine withdrawal is not consistently covered by insurance, and out-of-pocket costs can be significant. The cost-to-likely-benefit calculation is part of the decision.

    The Clinical View

    Dr. Leeds approaches advanced interventions like SGB with the same framework he applies to other adjuncts: they are tools, not solutions, and the underlying work of slow, patient-centered tapering remains the foundation. SGB may have a place for selected patients whose symptom pattern is consistent with sympathetic overdrive, who have stabilized their taper, and who are ready for an intervention that may produce meaningful relief without guarantees.

    For most patients, the highest-yield work is still the work that is hardest to articulate as a specific intervention: a careful taper rate, adequate time for the nervous system to settle between cuts, supportive medications used appropriately and not stacked indiscriminately, and an environment that does not amplify the symptom load. SGB sits alongside that work for some patients. It does not replace it for any of them.

    Patients who are interested in the procedure should have a conversation with their tapering physician about whether the timing is right and whether the symptom pattern fits what SGB plausibly addresses. The procedure is not a turning point that converts a difficult taper into an easy one, but for the right patient, it may offer a window of relief that other interventions have not provided.

  • Supporting the Caregiver: What Spouses and Family Members Need to Know About Benzodiazepine Withdrawal

    Supporting the Caregiver: What Spouses and Family Members Need to Know About Benzodiazepine Withdrawal

    Most of the writing about benzodiazepine withdrawal focuses on the patient, and rightly so. The patient is the one whose nervous system is dysregulated, whose sleep has collapsed, whose body has become a stranger to them. But there is a second person in nearly every difficult taper whose suffering is largely invisible: the spouse, partner, parent, adult child, or close friend who has stepped into the caregiver role. Their experience is shaped by the patient’s experience, but it is its own crisis, and it deserves direct attention.

    The caregiver role in benzodiazepine withdrawal is unlike most caregiving situations. There is no acute illness with a known timeline. There is no surgery to recover from. There is no medication that fixes the underlying problem on a predictable schedule. The caregiver is asked to support a person whose symptoms can shift hour by hour, who may be unrecognizable as themselves during the worst stretches, and whose recovery may take many months or even years. Most people who find themselves in this role were never prepared for it. Almost no one outside the immediate family understands what they are living through.

    The Invisibility of the Caregiver Role

    Caregivers of benzodiazepine patients describe a particular kind of isolation. The patient’s diagnosis is often unfamiliar to friends and extended family. Explaining what is happening requires teaching basic concepts about benzodiazepine dependence, BIND, and protracted withdrawal that most people have never heard of. The default response from people outside the situation tends to range from skepticism to unhelpful suggestions to a quiet pulling away as the months pass and the patient does not get better on a familiar timeline.

    The caregiver is often holding multiple roles at once. They are running the household. They are protecting the patient from inputs that worsen symptoms. They are managing communication with prescribers, pharmacies, and family. They are absorbing the emotional weight of watching someone they love suffer in ways that no one outside the family takes seriously. They may be carrying the financial weight of a partner who cannot work. They may be doing all of this while continuing to work themselves.

    And they are doing it with very little acknowledgment. The patient is the one in crisis, so the patient’s needs come first. The caregiver’s needs slide to the bottom of the list, often for so long that the caregiver stops registering them as needs at all.

    What Caregivers Actually Deal With

    Day to day, caregivers in benzodiazepine withdrawal situations are managing a moving target. The patient may be functional one day and bedridden the next. Sleep disruption affects the household, not just the patient. Sensory sensitivity may mean adjusting lighting, sound, and even cooking smells around what the patient can tolerate. Akathisia or severe waves can produce hours of pacing, distress, or inability to be alone. Mood changes can include irritability and anger that the patient may not even remember a day later.

    The caregiver becomes a kind of buffer between the patient and the outside world. Phone calls are managed. Visitors are screened. Medical appointments are scheduled and attended. Pharmacies are negotiated with. The caregiver often handles meals, household decisions, and financial matters that the patient cannot engage with during difficult periods.

    What is exhausting is not any single one of these tasks. It is the fact that all of them happen at the same time, that the situation cannot be predicted from one week to the next, and that there is no clear endpoint. The caregiver is running a marathon without knowing where the finish line is.

    Common Emotional Traps

    Several patterns appear repeatedly in caregivers of benzodiazepine patients, and recognizing them is the first step toward not getting caught in them.

    Believing recovery is around the corner. The hope that a wave is the last wave, that the next month will be the better month, that recovery will be linear, is natural but often inaccurate. Patients improve in non-linear ways, and caregivers who anchor their emotional state to expected timelines tend to be repeatedly disappointed. Letting go of the timeline, while painful, is more sustainable than chasing it.

    Taking the patient’s distress personally. A patient in active withdrawal may say things they would never say in a stable state. They may be irritable, withdrawn, accusatory, or unable to express gratitude. None of this is about the caregiver. Understanding that the dysregulated nervous system produces these moments helps the caregiver hold the relationship steady through them.

    Losing all of one’s own life. Caregivers who completely subordinate their own needs to the patient’s needs become depleted, and a depleted caregiver cannot sustain the role. Maintaining at least some continuity with one’s own friendships, interests, and physical health is not selfishness. It is what makes long-term caregiving possible.

    Searching for the missing intervention. Caregivers often spend hours researching supplements, treatments, and protocols, hoping to find the thing that will turn the corner. This research can be valuable, but it can also become a way of avoiding the harder reality: there may not be a missing intervention, and the patient may simply need time. Knowing when to keep searching and when to stop matters.

    Carrying it alone. Caregivers who do not develop their own support network outside the patient relationship tend to break down eventually. The caregiver needs at least one person, and ideally several, who knows what is happening, who can listen without trying to fix it, and who is willing to provide practical help when asked.

    Practical Strategies

    The strategies that help caregivers most are not complicated, but they require deliberate attention.

    Build a support network before the crisis worsens. Identify family members, friends, or members of the patient’s care team who can be called on during difficult stretches. The network is more useful when it is established before it is needed.

    Educate at least one or two people in the inner circle. Having a trusted person who understands the basics of benzodiazepine withdrawal means the caregiver can talk about what is happening without having to teach from scratch each time.

    Set up the household for sustainability. Meal preparation, errand handling, cleaning, and other routine tasks should be simplified or delegated where possible. The caregiver who is also doing every chore in the household will burn out faster.

    Protect sleep. The caregiver’s sleep matters as much as the patient’s. Separate sleeping arrangements during difficult periods are sometimes necessary and are not a failure of the relationship.

    Maintain regular medical care for yourself. Caregivers tend to defer their own appointments, ignore their own symptoms, and skip their own preventive care. Keeping the caregiver healthy is part of keeping the household functional.

    Build small windows of relief. A walk, a phone call with a friend, a few minutes alone in the car, a routine yoga class. Small windows that the caregiver can rely on are more sustainable than large interventions that have to be planned around the patient’s state.

    When to Reach Out for Additional Help

    Caregivers should reach for help if they are noticing their own depression deepening, their sleep failing for weeks, their physical health declining, or their patience eroding to the point that they are having difficulty being present for the patient. These are not character failures. They are signals that the load is exceeding what one person can carry without support.

    Therapists familiar with chronic illness or caregiver stress can help. Support groups, in person or online, that include other caregivers of benzodiazepine patients are particularly valuable because they remove the isolation that drives so much caregiver suffering. Family members who can take rotational responsibility, even for a few hours, are worth their weight in gold.

    Why Caregiver Well-Being Matters for Patient Recovery

    This is not just about the caregiver’s quality of life, although that matters in its own right. The patient’s recovery trajectory is shaped, in part, by the stability of their environment. A household held together by an exhausted caregiver is a different environment than a household held together by a caregiver who has the support they need. The patient is sensitive to those differences in ways they may not even consciously register.

    Dr. Leeds works with benzodiazepine patients who come into his practice with their family. The conversation includes the caregiver from the start. Their observations, their questions, and their well-being are part of the clinical picture. The patients who do best are typically the patients whose support system is also being supported.

    Caring for a person through benzodiazepine withdrawal is one of the hardest things a family member can do. The caregiver who is doing it deserves recognition, support, and the same patience they are extending to the person they love.

  • Akathisia During Benzodiazepine Withdrawal: The Restlessness Nobody Warns You About

    Akathisia During Benzodiazepine Withdrawal: The Restlessness Nobody Warns You About

    Akathisia is one of the most distressing experiences a person can have, and one of the least understood by clinicians who have not seen it in benzodiazepine patients. The word itself comes from a Greek root meaning “unable to sit,” but that translation does not capture what the experience actually feels like. Patients describe a relentless internal restlessness, a sense of needing to move that cannot be relieved by movement, a feeling of being driven from inside their own skin. It can produce pacing for hours, an inability to lie still, a sense that the body is being electrified, and a level of suffering that breaks down even patients who have weathered everything else withdrawal has thrown at them.

    Akathisia is not a fringe symptom of benzodiazepine withdrawal. It is one of the symptoms patients fear most, and one of the symptoms that most often goes unrecognized when patients show up in emergency rooms or psychiatric offices looking for help. Understanding what akathisia is, why it happens during benzodiazepine withdrawal, and what does and does not help is essential for patients living with it and for the clinicians trying to support them.

    What Akathisia Actually Is

    Akathisia is a movement disorder, but the movement is the visible part of a deeper neurological state. The patient’s nervous system has shifted into a pattern of dysregulation that produces a continuous feeling of needing to move, combined with a continuous failure of movement to provide any relief. A person with simple anxiety paces because they are anxious. A person with akathisia paces because they cannot stop, and the pacing does not help.

    The internal experience is what makes akathisia so difficult to convey. Patients describe it as restlessness multiplied many times over, as agitation that has no emotional cause, as a feeling of wanting to crawl out of their own body. Sleep becomes nearly impossible because lying still is intolerable. Sitting through a meal can feel like sitting on hot coals. Even the smallest tasks become exhausting because the body is constantly in motion or constantly demanding motion.

    This experience is often mistaken for severe anxiety, and the two can coexist, but they are not the same. Anxiety responds to calming inputs. Akathisia does not. A patient with akathisia will tell you that nothing they have tried touches it, and they are usually correct.

    Why Benzodiazepine Withdrawal Produces Akathisia

    Benzodiazepines work primarily through GABA-A receptors, the main inhibitory system in the central nervous system. Long-term benzodiazepine use leads to receptor adaptation: the system becomes less responsive to the medication and to the body’s own GABA. When the medication is reduced or removed, the inhibitory tone that was being maintained pharmacologically is no longer available. The nervous system is left in a state of relative excitation that the body has not yet reorganized to handle.

    That excitation does not show up uniformly. It manifests through whichever pathways are most vulnerable in the individual patient. In some patients it is sleep that breaks down. In others it is autonomic regulation. In others it is sensory processing. And in some, the pattern of dysregulation produces akathisia. The dopaminergic and adrenergic systems are involved, the GABAergic system is involved, and the result is a motor and sensory state that resembles the akathisia produced by certain antipsychotics, even though the trigger is entirely different.

    The Misdiagnosis Problem

    Patients with benzodiazepine-induced akathisia are routinely misdiagnosed. Emergency room clinicians, primary care physicians, and even psychiatrists who have not specifically encountered withdrawal-related akathisia often interpret the presentation as severe anxiety, agitated depression, or a panic state. The patient describes inability to sit still, racing internal feelings, and overwhelming distress. The diagnostic conclusion is usually that the patient needs more medication for their anxiety, not less.

    This misreading drives some of the worst clinical decisions made for benzodiazepine patients. A patient with akathisia from benzodiazepine withdrawal who is given a higher dose of benzodiazepine may feel briefly better and then feel worse. A patient given an antipsychotic for what is interpreted as agitation may have their akathisia made dramatically worse, because antipsychotics can produce akathisia of their own through a different mechanism. The original problem is not addressed, and the medication response often adds new layers of suffering.

    Recognizing akathisia for what it is, in the context of a benzodiazepine taper or a recent reduction, changes the entire treatment approach. The problem is not anxiety. The problem is a nervous system that has been pushed past what it can compensate for.

    What Standard Responses Get Wrong

    Several common clinical responses to akathisia during benzodiazepine withdrawal tend to make the situation worse rather than better.

    Adding antipsychotics is one of the most damaging. Quetiapine, risperidone, olanzapine, and similar medications carry their own risk of producing akathisia. For a patient already in a withdrawal-related akathisia state, adding an antipsychotic can compound the problem. The patient ends up with two overlapping akathisias driven by different mechanisms, and the second one will not resolve until the antipsychotic is removed.

    Increasing or reinstating benzodiazepines often produces partial relief that does not last. The dose needed to suppress the akathisia tends to climb. Reinstatement may be the right move for some patients in some contexts, but it is not a long-term solution for akathisia.

    Pushing the taper forward through severe akathisia is rarely the answer. Many patients have been told to “stay the course” when their nervous system is signaling that the rate of reduction is more than it can manage. Continuing to cut while in active akathisia tends to deepen the problem.

    What Can Help

    The honest answer is that no medication reliably eliminates withdrawal-related akathisia. There are interventions that sometimes reduce the intensity, and there are strategies that help the patient survive the experience until time and a stabilized nervous system bring the akathisia down.

    Slowing or pausing the taper is usually the first step. Akathisia often signals that the current rate of reduction is exceeding what the nervous system can absorb. Holding at the current dose, or even returning to a slightly higher prior dose, can give the system time to settle.

    Physical strategies that some patients find partial relief in include cold water on the face or hands, weighted blankets, slow rhythmic movement that the patient chooses rather than being driven into, and time outdoors with the kind of low-stimulation environment that does not amplify the sensory load. None of these is a treatment. They are tools that may help a patient endure the hours and days while the underlying state slowly improves.

    Beta blockers such as propranolol are sometimes used to reduce the adrenergic component, with mixed results. Hydroxyzine is sometimes useful at the margins. For some patients, a small amount of opioid analgesia produces relief that nothing else has touched, though this is rarely a sustainable approach. The most consistent finding is that there is no consistent answer, and patients respond differently.

    The Role of Time

    Akathisia driven by benzodiazepine withdrawal eventually subsides, but the time course is highly variable. Some patients see improvement within days of stabilizing the taper. Others live with significant akathisia for months. A subset of patients with protracted symptoms or BIND experience akathisia as a long-term feature that gradually softens over many months or years rather than weeks.

    This is why the work of recognizing akathisia early and adjusting the taper accordingly matters so much. The longer a patient remains in active akathisia, the harder the recovery process becomes. Dr. Leeds approaches akathisia as a signal that something is wrong with the rate of reduction, not as a symptom to medicate around. The most effective response is usually the one that addresses the underlying destabilization, supports the patient through the difficult window, and avoids interventions that risk making the akathisia worse.

    Patients who live through severe akathisia and come out the other side describe it as one of the most difficult experiences of their lives. The fact that it improves, and that patients do recover, is a piece of information worth holding on to during the worst of it.

  • Why the Ashton Manual Crossover Fails for Some Patients, and What to Do When Diazepam Provides No Relief

    Why the Ashton Manual Crossover Fails for Some Patients, and What to Do When Diazepam Provides No Relief

    The Ashton Manual is the foundational text on benzodiazepine tapering, and the crossover from a short-acting benzodiazepine to diazepam is one of its most influential recommendations. The logic is sound. Diazepam has a long half-life, which produces steadier blood levels and less between-dose withdrawal. It is available in low-dose tablets and as a liquid, which makes precise reductions easier. For many patients, the crossover works as intended and the rest of the taper proceeds more smoothly than it would have on the original drug.

    But the protocol does not work for every patient. A meaningful subset of people who attempt the crossover find that diazepam provides no relief, or worse, makes their symptoms more difficult. They are often left wondering whether they have misunderstood the protocol or whether something is wrong with them. Neither is true. The crossover has limits, and recognizing those limits early prevents weeks or months of unnecessary suffering.

    The Rationale Behind the Crossover

    The Ashton Manual recommends moving patients from short-acting benzodiazepines such as alprazolam, lorazepam, or clonazepam onto diazepam before beginning a slow reduction. The reasoning rests on three points. First, short-acting benzodiazepines produce steeper peaks and troughs in blood concentration, which can drive interdose withdrawal and reinforce dependence. Second, diazepam’s long half-life smooths out those swings. Third, diazepam comes in a wider range of low-dose preparations, which makes a slow taper more achievable.

    For a patient on a short-acting benzodiazepine who is otherwise stable, this protocol often works as advertised. The transition reduces interdose discomfort, the slower kinetics make the patient feel less reactive, and the taper proceeds at whatever pace the patient can tolerate.

    Where the Crossover Tends to Fail

    The patients who run into trouble with the crossover usually fall into one of several patterns.

    The patient is already destabilized. A patient who has been through tolerance withdrawal, a prior failed taper, or a period of kindling has a nervous system that responds differently to changes in benzodiazepine kinetics. Adding diazepam to that picture can produce more disruption than relief. The shift in receptor occupancy patterns, even when calculated correctly, may be enough to set off a wave of new symptoms.

    The receptor profile does not match. Benzodiazepines are not all the same at the receptor level. Clonazepam and alprazolam have binding patterns and downstream effects that diazepam does not fully replicate. A patient who has been on clonazepam for years may have a nervous system shaped around clonazepam-specific receptor occupancy. Diazepam, even at a calculated equivalent dose, may not feel the same.

    The patient is too far along. Crossover is most reliably useful early in tapering, before the dose has been reduced significantly. A patient who has already reduced from 2 mg of clonazepam to 0.5 mg over many months is in a different position than a patient just starting out. Introducing a new molecule at that stage often creates more variability than the patient can absorb.

    The patient has unique metabolism. Diazepam relies on hepatic metabolism through specific enzyme pathways. A subset of patients metabolize diazepam in ways that produce uneven blood levels or accumulation of active metabolites. For these patients, the long half-life that helps most people becomes a source of unpredictability.

    What “No Relief” Actually Looks Like

    When patients say diazepam is providing no relief, they usually mean one of several things. The new symptoms produced by the transition do not subside after the expected adjustment period of two to four weeks. The original symptoms the diazepam was meant to smooth out remain present at full intensity. New symptoms appear that the patient did not have on the original benzodiazepine. The patient feels more sedated without feeling more stable. Energy, sleep, and mood all feel worse rather than better.

    If these patterns persist beyond a reasonable adjustment window, it is unlikely that “more time” will resolve them. The crossover has reached the limit of what it can do for that particular patient.

    What to Do When the Crossover Fails

    The first decision is whether to complete the crossover, partially reverse it, or fully return to the original benzodiazepine. None of these options is automatically right. The choice depends on how far the crossover has progressed, how symptomatic the patient is, and what other variables are present.

    Returning to the original benzodiazepine. If symptoms became significantly worse during the crossover and have not improved, returning to the original drug at the prior stable dose is often the cleanest path. The patient can then taper directly from the original benzodiazepine using a liquid formulation or a compounding pharmacy preparation. This requires more precision than tapering from diazepam, but it avoids the receptor-shift problem.

    Tapering directly from the short-acting benzodiazepine. Patients on clonazepam, alprazolam, or lorazepam can be tapered directly using compounded liquid formulations or pill cutting at very small percentages. The Ashton Manual was written before compounding pharmacies were as widely available as they are now. Direct tapering, with appropriate precision, is a reasonable alternative when the crossover does not fit.

    Trying a partial substitution. Some patients do better with a mix of the original benzodiazepine and a small amount of diazepam, rather than a full crossover. The combination can offer some of the half-life smoothing without forcing a complete receptor shift. This approach requires careful monitoring and is less standardized than the full crossover, but it works for some patients.

    Holding before any further changes. A patient who has destabilized during a crossover often benefits from a period of holding at the current dose before any further moves. The nervous system needs time to settle, and additional changes during instability tend to compound the problem rather than solve it.

    The Clinical View

    Dr. Leeds approaches the Ashton crossover as one tool among several, not as a mandatory step. For patients who are stable, early in the taper, and on a short-acting benzodiazepine that is producing interdose withdrawal, the crossover is often the right move. For patients who are already destabilized, deep into a taper, or showing signs of receptor-level individuality, the crossover may not fit. The protocol is a starting point, not a verdict.

    What unites every successful taper is the willingness to listen to what the patient’s nervous system is reporting. When diazepam provides no relief, that is data. The right response is to adjust the plan, not to insist the protocol must work given enough time.

  • Gabapentin Dependence: The Overlooked Deprescribing Challenge

    Gabapentin Dependence: The Overlooked Deprescribing Challenge

    Gabapentin is prescribed for an expanding list of conditions: neuropathic pain, partial seizures, fibromyalgia, restless legs, anxiety, insomnia, alcohol withdrawal, and opioid-sparing postoperative analgesia. The prescribing profile has grown considerably faster than the evidence base, and the drug’s reputation as a benign, non-controlled alternative to benzodiazepines and opioids has produced a cohort of patients who are physically dependent on gabapentin with little recognition of that fact by their prescribers.

    The word “dependence” here is narrow. Gabapentin has modest abuse potential — particularly in polysubstance users, particularly at supratherapeutic doses — but that is not the common clinical problem. The common problem is iatrogenic physical dependence in patients taking prescribed doses, who cannot stop the medication without significant withdrawal symptoms and who are rarely warned that this is possible.

    Pharmacology, Briefly

    Despite its name, gabapentin does not act directly on GABA-A receptors. It binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing presynaptic calcium influx and attenuating excitatory neurotransmitter release — particularly glutamate, but also norepinephrine and substance P. This mechanism underlies its analgesic, anxiolytic, and anticonvulsant effects. The relevance to dependence is that chronic suppression of calcium channel function produces compensatory adaptations; when the drug is removed, the channel activity rebounds, producing a state that clinically resembles benzodiazepine withdrawal in many features.

    Recognizing Physical Dependence

    Physical dependence on gabapentin emerges on a predictable timescale — usually weeks to a few months of consistent dosing. Patients do not typically describe it as dependence; they describe the following.

    Rebound symptoms when a dose is missed or delayed. Anxiety, irritability, insomnia, headache, or return of the original pain complaint within 12 to 24 hours of a missed dose.

    Dose-inflexibility. Attempts to lower the dose produce symptoms that the patient interprets as return of the underlying condition, leading back to the original dose.

    New symptoms on stable dose. Some patients develop a syndrome that resembles tolerance: anxiety, insomnia, restless sensations, or cognitive symptoms that were not present at baseline and are incompletely relieved by the next dose.

    The Withdrawal Syndrome

    Acute gabapentin withdrawal in a physically dependent patient can include anxiety, insomnia, tremor, sweating, nausea, headache, palpitations, and restlessness. Reports of withdrawal seizures exist, particularly after abrupt discontinuation of high-dose regimens. In patients with histories of benzodiazepine exposure or other GABA-system involvement, the withdrawal picture can be indistinguishable from benzodiazepine withdrawal, which makes separating cause and contribution difficult when the two medications are being tapered simultaneously.

    A protracted course has been described but is less well characterized than in benzodiazepines. Some patients report months of residual symptoms after discontinuation, including heightened sensory sensitivity and autonomic features.

    Why Deprescribing Is Overlooked

    Several structural factors contribute.

    The first is the prescribing context. Gabapentin is often added opportunistically — to manage pain during a benzodiazepine taper, to address insomnia from SSRI withdrawal, to provide an opioid-sparing adjunct after surgery — with no exit strategy defined. The initial prescription tends to become the chronic prescription.

    The second is the drug’s low-profile reputation. Because gabapentin is not federally scheduled (it is controlled in some states; pregabalin carries Schedule V status federally), prescribers treat it as low risk and rarely initiate a deprescribing conversation.

    The third is diagnostic confusion. When a patient’s attempt to reduce gabapentin produces anxiety and insomnia, the default interpretation is that the original indication has returned and requires continued treatment. The withdrawal framework is often not considered.

    How to Approach Deprescribing

    The principles parallel what the Ashton Manual and Maudsley Deprescribing Guidelines (Horowitz and Taylor, 2024) recommend for benzodiazepines, with some adjustments specific to gabapentin pharmacology.

    Slow taper. Reductions of 10% per month from current dose, with smaller reductions as the dose falls, are well tolerated by most patients. Faster protocols sometimes work in short-exposure patients; slower protocols are needed for patients with years of use or concurrent benzodiazepine exposure.

    Dose redistribution before reduction. For patients on twice-daily dosing, shifting to three-times-daily dosing before starting reductions can reduce interdose symptoms and make subsequent reductions more tolerable.

    Liquid or compounded formulations at lower doses. Once the dose is below 300 mg daily, tablet strengths limit precision, and a compounded liquid allows smooth reductions.

    Parallel tapers with caution. If a patient is tapering both a benzodiazepine and gabapentin, the usual recommendation is to taper one at a time rather than both simultaneously. Which to do first depends on the clinical picture and the symptoms driving the decision, but running both tapers in parallel multiplies the withdrawal burden in a way most patients cannot sustain.

    Hold through flares. Dose holds during symptom exacerbations work in the same way they do for benzodiazepines — buying time for the nervous system to adapt before the next reduction.

    Gabapentin Added During a Benzodiazepine Taper

    A specific clinical question is whether gabapentin should be added during a benzodiazepine taper to manage withdrawal symptoms. The short answer is: rarely, and not without a deprescribing plan defined before the first dose is given.

    Adding gabapentin to a benzodiazepine taper can produce short-term symptom relief. It also produces a new dependence with its own withdrawal course, and the patient then faces two tapers instead of one. For some patients — particularly those with intractable neuropathic pain or seizure disorders — the trade-off may still be favorable. For most, it is not.

    Patients who find themselves on gabapentin that was added during a prior benzodiazepine taper, and who are now facing the gabapentin taper as a second problem, are a recognizable clinical population. The solution is not to accelerate either taper but to complete them sequentially, with adequate time for stabilization between.

    What to Ask For

    Patients who suspect they may be physically dependent on gabapentin can raise the question directly with their prescriber. Useful framings: “I’d like to understand what happens if I stop this medication,” “what is the deprescribing plan,” and “what would a slow taper look like.” The absence of a clear answer to these questions is itself useful information.

    Gabapentin dependence is a clinical reality that the current prescribing culture around the drug does not reliably recognize. Addressing it requires treating gabapentin with the same care that benzodiazepines are increasingly receiving — which is to say, acknowledging that long-term use produces adaptations, and that removal requires planning.

  • Kindling and Benzodiazepines: Why Failed Tapers Make the Next One Harder

    Kindling and Benzodiazepines: Why Failed Tapers Make the Next One Harder

    Kindling, in the addiction and withdrawal literature, refers to the phenomenon in which repeated cycles of withdrawal produce progressively worse withdrawal syndromes on each subsequent cycle. The mechanism was first characterized in alcohol dependence by Robert Post and others in the 1980s, where the observation was clinical and unambiguous: patients with histories of multiple detoxifications from alcohol had more severe, more medication-resistant, and more seizure-prone withdrawal courses than patients undergoing a first detox. The same framework, with stronger and weaker evidence depending on the specific claim, has been extended to benzodiazepines.

    For patients who have attempted and failed one or more benzodiazepine tapers, this matters. Each failed attempt may not be a neutral event; the preliminary evidence suggests that the next attempt is starting from a harder place than the first.

    What Kindling Actually Describes

    Two overlapping phenomena are usually bundled under the term.

    The first is neuronal sensitization. Repeated withdrawal episodes produce lasting changes in excitatory and inhibitory neurotransmission that lower the threshold for symptom emergence and seizure on subsequent withdrawals. The word “kindling” is borrowed from the experimental model in which repeated subthreshold electrical stimulation of the amygdala eventually produces spontaneous seizures at intensities that were originally subthreshold. The withdrawal application extends this: repeated subthreshold excitatory episodes — withdrawal-induced hyperexcitability — produce durable changes in the circuitry’s response to subsequent insults.

    The second is behavioral or affective sensitization. Each withdrawal episode produces more severe subjective symptoms than the last, independent of any measurable seizure threshold. Patients report that a second or third attempt at a taper is “not just the first withdrawal again” but is qualitatively more intense, more protracted, and more refractory to standard symptom management.

    The Evidence in Benzodiazepines

    The kindling literature in benzodiazepines is not as robust as in alcohol, but several lines of evidence converge.

    Animal work demonstrates that repeated withdrawal from chronic benzodiazepine administration produces increasing signs of withdrawal severity and, in some paradigms, reductions in GABA-A receptor function beyond what single-cycle withdrawal produces.

    Clinical observation, accumulated across decades of case series and the Ashton Manual’s patient cohorts, describes a recognizable pattern in which patients who have attempted rapid detox, or who have cycled off and back on benzodiazepines multiple times, present with withdrawal courses that are unusually severe and prolonged relative to their total benzodiazepine exposure.

    The overlap with patients who later develop features consistent with benzodiazepine-induced neurological dysfunction (BIND) is notable. Ritvo and colleagues’ 2023 description of BIND includes multiple withdrawal attempts as a feature in a meaningful proportion of the reported cohort.

    The mechanism is not fully characterized. Candidates include glutamatergic upregulation, persistent alterations in GABA-A receptor subunit composition, secondary neuroinflammation, and HPA axis changes. Whichever mechanism or combination is operative, the clinical implication is the same: the safest number of taper attempts is one successful one.

    What This Means for Taper Strategy

    The priority when a patient has a history of one or more failed tapers is not simply to “try again with more conviction.” Three considerations follow from the kindling framework.

    First, pace should be even slower than standard. If a taper at 5% per month was intolerable last time, restarting at 5% per month is not a reasonable plan. Starting at 2.5% or lower, with hyperbolic reductions that decrease as the dose falls, is the pattern most consistent with the Maudsley Deprescribing Guidelines’ approach to patients with complicated histories.

    Second, stabilization before reduction is not a sign of failure. Patients who have kindled often need weeks to months at a stable dose before they can tolerate any further reduction. This is not time wasted; it is time during which the nervous system is not being re-provoked into another withdrawal episode. A taper that does not move for two months in a kindled patient is a better outcome than a taper that moves quickly and fails again.

    Third, the temptation to abandon a slow taper for a faster alternative is particularly dangerous in this population. The patient who has already failed one rapid detox is the patient whose next rapid detox is most likely to produce severe protracted harm. The arithmetic does not improve with repetition.

    Managing a Kindled Patient

    Several practical principles apply.

    Switch to a longer-acting agent if feasible. Interdose withdrawal on short-acting benzodiazepines is itself a form of micro-withdrawal and, in a kindled patient, should be minimized. A carefully executed Ashton-style substitution to diazepam can stabilize the interdose period before tapering resumes. The Maudsley Deprescribing Guidelines offer refined substitution ratios and a more cautious approach for complex cases.

    Use liquid or compounded formulations when the dose becomes too low for commercially available tablet fractions. Precision matters more in kindled patients; a 12.5% dose reduction is different from a 10% reduction at these dose levels, and approximate cutting produces approximate results.

    Hold the dose through exacerbations. A kindled patient in a symptom flare who reduces dose anyway is likely to worsen. Holding — sometimes for weeks — is usually the correct move.

    Coordinate with a clinician who will not push. The single most common path to repeated kindling is a prescriber who interprets the patient’s reasonable request to slow down as non-adherence and continues to move the dose anyway. A collaborative taper is a kindling-reducing intervention in itself.

    A Note on Patients Who Have Already Kindled

    Patients in this category often arrive having been told that their severe symptoms on prior attempts were psychosomatic, psychiatric, or reflective of underlying personality features. The kindling framework reframes the same clinical observation in neurobiological terms. This is not a minor point for the patient’s treatment or their engagement with a subsequent attempt; a patient who believes their problem is their psychology is harder to taper than a patient who understands they are managing a sensitized nervous system.

    The pattern of failed tapers making subsequent tapers harder is real, and it is the single strongest argument for getting the first attempt right. For patients who are past that point, the work now is to approach the next attempt with enough caution to keep it from becoming another data point in the kindling series.

  • Tolerance Withdrawal: Benzo Symptoms Before the Taper Begins

    Tolerance Withdrawal: Benzo Symptoms Before the Taper Begins

    Benzodiazepine withdrawal is usually discussed as what happens after the taper — the symptoms that emerge as the dose comes down. But a substantial number of long-term benzodiazepine patients are already in withdrawal while they are still taking their medication at the prescribed dose. This is tolerance withdrawal, and recognizing it matters clinically because it changes what the taper is actually doing.

    The phenomenon is documented in the Ashton Manual and elsewhere in the benzodiazepine literature as the state in which the original therapeutic effect of the medication has been lost while the patient remains on it. The anxiety or insomnia that the benzodiazepine was originally prescribed for returns, often with new features, and the patient typically concludes — along with the prescriber — that the original condition has worsened and needs a higher dose. It has not necessarily worsened. The receptors have adapted.

    How Tolerance Develops

    GABA-A receptors are the inhibitory infrastructure of the central nervous system. Benzodiazepines act as positive allosteric modulators at these receptors, increasing the frequency of chloride channel opening in response to endogenous GABA. With prolonged exposure, the receptor complex adapts: subunit composition shifts, receptor density decreases, and the magnitude of response to a given benzodiazepine dose falls. The clinical result is that the dose that produced the original anxiolytic or hypnotic effect stops producing it. The patient is now receiving the drug for a nervous system that has reshaped itself around it.

    Recognizable Features

    Tolerance withdrawal looks different from a straightforward relapse of the original condition, though the distinction is frequently missed in a brief clinic visit. Several features are characteristic.

    Symptoms that were not present before the benzodiazepine was started. Patients often report new physical phenomena — perioral numbness, paresthesias, muscle twitching, inner tremor, photophobia, hyperacusis, gastrointestinal symptoms, tinnitus — that were absent at baseline and do not fit the original diagnosis.

    Interdose symptoms with short-acting agents. Patients on alprazolam or lorazepam frequently describe a time-locked pattern: symptoms build through the interdose interval and are briefly relieved by the next dose. This is indistinguishable in form from a short-acting withdrawal course and essentially confirms tolerance.

    Failure of dose increases to hold. A dose increase produces transient improvement, often only for a few weeks, before symptoms return at the new dose. The ladder keeps climbing without producing sustained relief.

    Morning worsening. Overnight metabolism of the drug can produce a morning low point with agitation, anxiety, or physical symptoms that resolve an hour or two after the morning dose. The pattern is again time-locked to pharmacokinetics, not to the patient’s day.

    Sensory sensitivity and autonomic features. Heightened startle, light or sound sensitivity, temperature dysregulation, and episodes of tachycardia are common and typically unrelated to the patient’s original presenting complaint.

    Why This Is Usually Missed

    The clinical problem is structural. A patient who presents with worsening anxiety on a long-term benzodiazepine prescription typically receives a dose increase or a second psychotropic. Neither intervention addresses tolerance. The dose increase buys a few weeks; the second agent (often an SSRI or a neuroleptic prescribed for sleep) adds new pharmacologic variables without resolving the underlying adaptation.

    Two features of the standard office visit contribute. First, most prescribers have limited exposure to the tolerance literature; the framework is not a default diagnostic consideration for new anxiety complaints. Second, the symptom pattern overlaps genuinely with primary anxiety disorders, and a time-limited visit cannot easily distinguish a patient in tolerance withdrawal from a patient whose original condition is worsening. The prescription environment therefore drifts toward dose escalation and polypharmacy.

    Clinical Implications for the Taper

    Tolerance withdrawal changes what a taper means. A patient who is already in withdrawal on their current dose is not going to experience the first several reductions as introducing new symptoms; they are going to experience them against a baseline that already includes withdrawal features. This has several practical consequences.

    The first is that a very slow initial pace is often better tolerated than a standard one. Patients in tolerance withdrawal frequently stabilize partially during the first weeks of a taper — paradoxical as that sounds — because stable receptor conditions begin to reassert themselves once the dose stops being a moving target.

    The second is that interdose stabilization sometimes matters more than dose reduction, especially for short-acting agents. Switching a patient from alprazolam to an equivalent dose of a longer-acting benzodiazepine such as diazepam (the Ashton substitution) can reduce interdose symptoms and make subsequent dose reductions more tolerable. This is not always the right move — the Maudsley Deprescribing Guidelines (Horowitz and Taylor, 2024) refine the Ashton substitution and treat it as one tool rather than a universal step — but it is worth considering early.

    The third is that treating tolerance withdrawal as if it were an indication for dose increase is actively harmful. The reflex to add dose, or to add another medication, when a patient on a long-term benzodiazepine develops new symptoms is, in this population, the step that produces the most downstream harm. Recognizing tolerance as a possibility changes the conversation from “how much more do we add” to “how do we unwind this safely.”

    What Patients Can Bring to a Visit

    For patients who suspect they are in tolerance, several things help at the prescriber visit.

    A symptom timeline: when each symptom first appeared, in relation to starting or increasing the benzodiazepine or to dose timing within the day. Handwritten is fine; dated is essential.

    A dose history: drug, dose, frequency, and any escalations over time.

    The specific concern framed as tolerance, not relapse. “These symptoms are new and time-locked to dosing” is a different clinical question from “my anxiety is worse.”

    A willingness to discuss a taper. Many prescribers will not initiate the tolerance conversation, but most will engage with it if the patient raises the possibility directly.

    Tolerance withdrawal is not a rare presentation. It is common, under-recognized, and the most reliable predictor of the patients who arrive later in protracted withdrawal with symptoms that have been accumulating for years. Identifying it early is the single intervention most likely to change the trajectory.